{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:03:59Z","timestamp":1777727039832,"version":"3.51.4"},"reference-count":13,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.3892\/mco.2017.1349","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T10:25:37Z","timestamp":1500978337000},"page":"383-385","source":"Crossref","is-referenced-by-count":18,"title":["Osimertinib-induced interstitial lung disease in a patient with non-small cell lung cancer pretreated with nivolumab: A case report"],"prefix":"10.3892","volume":"7","author":[{"given":"Osamu","family":"Takakuwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Oguri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehiro","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Sone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minami","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Kanemitsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Ohkubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaya","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Maeno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Niimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"key20180107151212_b1-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small cell lung cancer","volume":"372","author":"J\u00e4nne","year":"2015","journal-title":"N Engl J Med"},{"key":"key20180107151212_b2-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"key20180107151212_b3-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"key20180107151212_b4-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"key20180107151212_b5-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"key20180107151212_b6-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180107151212_b7-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20180107151212_b8-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/JTO.0b013e3181ca12e0","article-title":"Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: The Okayama Lung Cancer Study Group experience","volume":"5","author":"Hotta","year":"2010","journal-title":"J Thorac Oncol"},{"key":"key20180107151212_b9-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1016\/S1556-0864(16)30246-5","article-title":"136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial","volume":"11","author":"Ahn","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20180107151212_b10-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S1556-0864(16)30171-X","article-title":"570 Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-na\u00efve patients (pts) with EGFR mutant NSCLC","volume":"11","author":"Gibbons","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20180107151212_b11-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20180107151212_b12-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-A meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"key20180107151212_b13-mco-0-0-1349","doi-asserted-by":"crossref","first-page":"73068","DOI":"10.18632\/oncotarget.12230","article-title":"The efficacy and safety of anti-PD-1\/PD-L1 antibodies for treatment of advanced or refractory cancers: A meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T09:17:47Z","timestamp":1602580667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2017.1349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":13,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,7,25]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.3892\/mco.2017.1349"],"URL":"https:\/\/doi.org\/10.3892\/mco.2017.1349","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]}}}